Conference Coverage

Wrap-Up: Optimizing Outcomes in Patients with Inflammatory Bowel Disease

Joel Heidelbaugh, MD

In this video, Joel Heidelbaugh, MD, provides an overview of the session Optimizing Outcomes in Patients with Inflammatory Bowel Disease: Strategies to Improve Disease Management in Primary Care at PUPC 2023, including current guidelines in the multidisciplinary approach to the management of patients with IBD to optimize patient outcomes.

For more meeting coverage, visit the Practical Updates in Primary Care newsroom.

For more information about PUPC 2023 Virtual Series and to register for upcoming sessions, visit https://www.practicalupdates.consultant360.com/.

Joel Heidelbaugh, MD, is a family physician at the University of Michigan Medical School (Ann Arbor, MI).

TRANSCRIPTION:

Dr Joel Heidelbaugh: Hi, I'm Dr Joel Heidelbaugh, family physician from the University of Michigan in Ann Arbor, Michigan. And thank you very much for participating in our program today on inflammatory bowel disease. And I'd like to also thank you on behalf of my colleagues who presented this program with me today, Dr Pabla and our patient advocate, Sneha Dave. We find this to be a very rich program, and we hope you enjoyed it and learned a lot as well. If you did not have the opportunity to participate in this program, we invite you to participate when we air it again in July.

Just some key summary and take home points. We've presented both the primary care and gastroenterology perspectives here today highlighting the importance of recognizing the disease, early diagnosis and appropriate therapeutic workup. And then we've highlighted a number of current evidence-based therapies and guidelines for treatment. The one key take home I think is important is that inflammatory bowel disease is not housed within either gastroenterology or primary care. This is a multidisciplinary approach to managing the needs of these patients, both longitudinally for collective care, but also health maintenance and monitoring of potential adverse effects while we aim for remission. So, I'm glad you enjoyed the program and we look forward to seeing you again for additional programs in the future.